Anika Therapeutics director granted 14,164 RSUs; stake rises to 47,871

Accepted by SEC EDGAR 06/24/2025 - 05:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anika Therapeutics (NASDAQ:ANIK) filed a Form 4 reporting that director Stephen Richard received 14,164 restricted stock units (RSUs) on 06/20/2025 at a cost basis of $0. The RSUs vest in full on the earlier of the 2026 annual shareholder meeting or 06/20/2026. After the grant, Richard’s direct beneficial ownership increased to 47,871 common shares.

The filing reflects a routine board compensation award; no open-market purchases or sales were disclosed.

Insider Trade Summary

Grant/Award: 14,164 shares

Grant/Award 1 txn

Insider Richard Stephen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,164	$0.00	$0.00

Holdings After Transaction: Common Stock — 47,871 shares (Direct)

Holdings Before and After: Common Stock, 33,707 to 47,871 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anika Therapeutics (ANIK) disclose in the June 2025 Form 4?

The company reported that director Stephen Richard received 14,164 RSUs on 06/20/2025, increasing his direct holdings to 47,871 shares.

When will the newly granted RSUs to Stephen Richard vest?

All RSUs vest on the earlier of the 2026 annual shareholders’ meeting or June 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richard Stephen

(Last) (First) (Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		14,164(1)	A	$0	47,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

	/s/ Stephen Richard	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.